All In Biotech

Drug Trial Radar · NCT05085990

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

A Phase 1a/b Dose Finding, Open-label Study to Evaluate Safety and Toxicity of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer

Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

May 8, 2023

Primary completion

Sep 12, 2024

Study completion Sep 12, 2024

Sponsor

Lead sponsor
Protara TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open-label dose expansion study to investigate the safety and toxicity of intravesical treatment of high-grade NMIBC (HGTa or CIS, including CIS with concomitant Ta) after transurethral resection of bladder tumor (TURBT) and/or biopsy using TARA-002 in adults unable to obtain intravesical Bacillus Calmette-Guérin (BCG), adults who have received at least one dose of intravesical BCG or adults who have received at least one dose of intravesical chemotherapy. After completion of the dose escalation phase (Phase 1a) and after the RP2D has been established, the dose expansion phase (Phase 1b) will start enrollment of subjects with CIS NMIBC with active disease to further evaluate the safety and preliminary efficacy of TARA-002, at the established RP2D. CIS NMIBC with active disease is defined as disease present at the last cystoscopic evaluation prior to signing the ICF. Subjects enrolled in the dose expansion phase will not include subjects previously enrolled and treated in the dose escalation phase. All subjects will receive 6 weeks of treatment at the established RP2D.

Conditions

  • Non-muscle Invasive Bladder Cancer

Interventions

  • TARA-002Biological

    Phase 1b, Dose Expansion Phase: All subjects will receive 6 weekly doses of TARA-002 at the recommended Phase 2 dose (R2PD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b, Dose Expansion Phase: Incidence of AEs in subjects with CIS NMIBC with active diseaseTime frame: Day 1 to Day 78

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • USC Norris Cancer Center

    Los Angeles, California

  • Mayo Clinic

    Jacksonville, Florida

  • Tulane Medical Center (TMC) - Clinic/Outpatient Facility

    New Orleans, Louisiana

  • Chesapeake Urology Research Associates

    Baltimore, Maryland

  • Mayo Clinic

    Rochester, Minnesota

  • Premier Medical Group of the Hudson Valley

    Poughkeepsie, New York

  • University of Rochester, Department of Urology

    Rochester, New York

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Urology Associates PC

    Nashville, Tennessee

  • UT Health San Antonio

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.